2012 Best of ASCO Boston

Lung Cancer

Biomarker-driven Adaptive Trial Design Proving Informative in Non–Small Cell Lung Cancer

Biomarker-driven adaptive trial design is an accelerated strategy for targeted drug development that is proving informative in non–small cell lung cancer (NSCLC), according to Roy S. Herbst, MD, PhD, ...

Skin Cancer

Exciting New Agents Offer Further Treatment Options for Metastatic Melanoma

“This is a very exciting time in melanoma,” said Michael Sabel, MD, of the University of Michigan, Ann Arbor. “For years, we chugged along with few options for systemic therapy. Then in 2010 and 2011,...

Solid Tumors
Kidney Cancer

Another Tyrosine Kinase Inhibitor Joins the Lineup in Renal Cell Carcinoma

The novel tyrosine kinase inhibitor tivozanib was superior to sorafenib (Nexavar) for the treatment of advanced renal cell carcinoma in the phase III TIVO-1 trial.1 Tivozanib is a potent, selective in...

Prostate Cancer

Novel Drugs Enhance—but Complicate—Prostate Cancer Treatment

Three emerging agents for castration-resistant prostate cancer are extending lives and defining their roles in the treatment scenario, according to William Oh, MD, of Mount Sinai School of Medicine, N...

Encouraging Data Presented for Monoclonal Antibodies and Novel Oral Agent in Lymphocytic Leukemias

Novel agents may transform the outcomes of lymphocytic leukemias. In acute lymphocytic leukemia (ALL), encouraging data were presented for two monoclonal antibodies, and in chronic lymphocytic leukemi...

Leukemia

New Agents Are Achieving Deeper Responses in CML

As tyrosinse kinase inhibitors become increasingly effective in treating chronic myeloid leukemia (CML), major molecular responses (≥ 3-log reduction in BCR-ABL transcripts) are being achieved for a g...

Multiple Myeloma

Will Carfilzomib Add Value to Multiple Myeloma Treatment?

Carfilzomib (Kyprolis), the next-generation proteasome inhibitor recently approved by the FDA for relapsed/refractory multiple myeloma, showed strong activity in the front-line setting when paired wit...

Lymphoma

ABVD and BEACOPP Yield Equivalent Survival in Hodgkin Lymphoma

In the EORTC 20012 randomized phase III trial comparing eight cycles of ABVD vs eight cycles of BEACOPP, Hodgkin lymphoma patients achieved equivalent overall survival with either regimen, but BEACOPP...

Lymphoma

Which Rituximab-based Regimen Works Best in Non-Hodgkin Lymphoma?

The treatment of non-Hodgkin lymphoma (NHL) patients has been recently informed by several important studies, which were discussed at the Best of ASCO Boston meeting by Michael E. Williams, MD, of the...

Breast Cancer

Refining Current Treatments and Looking Ahead in HER2-positive Breast Cancer

In a study presented at the ASCO Plenary Session, trastuzumab emtansine (T-DM1), the antibody-drug conjugate linking trastuzumab (Herceptin) to a cytotoxic agent, improved progression-free survival by...

Breast Cancer

Cytotoxic Chemotherapy for Breast Cancer: Are We Done Tweaking It?

While novel targeted agents may grab the headlines in the treatment of breast cancer, oncologists still debate the optimal delivery of conventional cytotoxic chemotherapy, still a vital component of t...

Solid Tumors
Breast Cancer
Leukemia

New Studies Explore Exposure to Cancer-causing Agents

Key studies on cancer epidemiology and prevention delivered both reassuring and not-so-reassuring findings on exposure to agents believed to be cancer-promoting. Kala Visvanathan, MD, MHS, of The Sidn...

Sarcoma

For Advanced Sarcomas, New Agents Prolong Remission but Not Survival

“We are beginning to understand the molecular biology underlying a portion of the 80 or so subtypes of sarcomas, and we hope this will lead to subtype-specific treatments,” said William D. Tap, MD, of...

Breast Cancer

Childhood Radiation Increases Breast Cancer Risk

The risk of developing breast cancer after receiving radiotherapy to the chest as a child are as high as those for BRCA1/2 mutation carriers, according to review of 1,268 cancer survivors and 4,570 fe...

Breast Cancer

In DCIS, Radiotherapy Benefits ‘Good Risk’ Patients

Radiation therapy will improve outcomes for patients with ductal carcinoma in situ (DCIS), even if they are considered at low risk for recurrence, according to the Radiation Therapy Oncology Group (RT...

Advertisement

Advertisement



Advertisement

click me